MicroCoil treatment for aneurysms to enter trials:
This article was originally published in Clinica
Executive Summary
Micrus is to begin US clinical trials of its minimally invasive treatment for intracranial aneurysms under an investigational device exemption from the FDA. The ACT MicroCoil delivery system releases coils into the aneurysm, which isolate it from arterial flow and reduce its chances of rupture or re-rupture. Rupture of intracranial aneurysms can lead to stroke and death if untreated, said the Mountain View, California based company. Micrus estimated that the worldwide market value of its product could be worth more than $100 million annually.